Robert Erwin

Chairman, Oryn Therapeutics
President, iBio, Inc., Chairman, Novici Biotech

Mr. Erwin is a veteran of the biotechnology sector. He was chief executive officer of Large Scale Biology Corporation from 1992 to 2003 and served as its chairman until 2006. He was chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. From 2003 until 2007 he was managing director of Bio-Strategic Directors LLC, a life science-industry consulting firm focused on intellectual property and strategy. He served as a member of the National Cancer Policy Forum of the Institute of Medicine, a the Research Committee of the American Society of Clinical Oncology, and the Data and Safety Monitoring Board of the Cancer and Leukemia Group B. He is currently president of iBio, Inc., a public biotechnology company in New York, NY, and chairman of Novici Biotech LLC in Vacaville, California. He is also managing member of Biospecimen Technologies LLC and serves on the board of the Marti Nelson Cancer Foundation. He is an inventor on several issued and pending patents.

Michael Selsted, M.D., Ph.D.

Chief Scientific Officer, Oryn Therapeutics
Professor & Chair, Department of Pathology, Keck School of Medicine of USC

Dr. Selsted received his Ph.D. and M.D. degrees from UCLA where he also completed his residency training in Clinical Pathology. Prior to his appointment at USC in 2009, Dr. Selsted was Professor and Chair of Pathology at the UC Irvine School of Medicine, serving in that role for nearly 10 years. Dr. Selsted is widely known for his research in the field of immunology, and is co-discoverer of host defense peptides called defensins. He has more than 135 publications to his credit, and is named as an inventor on 28 U.S. patents. Dr. Selsted is Professor and Chairman of the Department of Pathology at the Keck School of Medicine at the University of Southern California where is also Director of Laboratories at Norris Cancer Hospital and USC University Hospital.

Percio S. Gulko, M.D

Chief Medical Officer, Oryn Therapeutics

Percio S. Gulko, M.D. is the Lillian and Henry M. Stratton Professor of Medicine and Chief of Rheumatology at the Icahn School of Medicine at Mount Sinai. Prior to his appointment at Mt. Sinai, he was Professor of Molecular Medicine and Rheumatology and a Laboratory Head at the Feinstein Institute for Medical Research. This position was preceded by a faculty position in the Columbia University College of Physicians and Surgeons. Dr. Gulko received his M.D. from the Universidade Federal do Rio Grande do Sul, Brazil, his medicine residency at Medical College of Georgia and his rheumatology fellowship at the National Institutes of Health. Dr. Gulko’s research, primarily funded by NIH, has focused on the pathogenesis of rheumatoid arthritis and the regulation of the inflammatory response. His laboratory identified new genes implicated in the regulation of arthritis severity and joint damage and has done extensive work to understand processes that regulate the invasive properties of the synovial fibroblast.

Richard Selsted

Chief Operating Officer, Oryn Therapeutics

Mr. Selsted joined Oryn’s Executive Team in September 2014. He is responsible for Operations, Marketing, and Corporate Development. Prior to joining Oryn, Mr. Selsted ran the largest Cloud business unit at SAP, the world’s largest software applications company. Mr. Selsted’s business unit covered 13 countries and over 3500 clients. Prior to Mr. Selsted’s career at SAP, he held various executive positions at Oracle Corporation, Siebel Systems, and Solidus Networks. Mr. Selsted holds a bachelor’s degree in environmental sciences from the University of California, Berkeley.

Kimberley V. Rogers, Ph.D

Vice President - Business Development, Oryn Therapeutics

Dr. Rogers brings over 25 years of experience in the biotechnology and pharmaceutical fields. She has an established track record of successfully building product development plans and business plans to support licensing and financing transactions. Formerly Kimberly was the Vice President of Technology Assessment at Allergan where she was responsible for search and technical evaluation of potential pharmaceutical product in-license/acquisition opportunities to support expansion of the Company’s product pipeline. Prior to her role at Allergan, Kimberly worked for both start-up and mid-sized pharmaceutical companies in both scientific, business development and strategic planning roles. Kimberly holds a BS from the University of California Santa Barbara and a PhD in Physiology and Biophysics from the University of Washington.